Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 14/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | CD38 | P28907 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | USP1 | O94782 | 1/20 | 0.43 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16796125 | 0.91 | RPS6KB1 (0.53) | VCPRPS6KB1AURKAJAK2JAK1 | |
| SCHEMBL16796100 | 0.90 | VCP (0.52) | VCPRPS6KB1AURKACD38PRKDC | |
| SCHEMBL16796233 | 0.90 | VCP (0.49) | VCPRPS6KB1AURKACD38PRKDC | |
| SCHEMBL16796046 | 0.89 | VCP (0.49) | VCPRPS6KB1AURKACD38PRKDC | |
| SCHEMBL16796246 | 0.89 | VCP (0.53) | VCPRPS6KB1AURKACD38PRKDC | |
| SCHEMBL16796372 | 0.89 | VCP (0.49) | VCPRPS6KB1AURKACD38PRKDC | |
| SCHEMBL16796275 | 0.85 | VCP (0.72) | VCPPRKDC | |
| SCHEMBL19771687 | 0.83 | VCP (0.60) | VCPRPS6KB1AURKACD38PRKDC | |
| SCHEMBL15558133 | 0.82 | VCP (0.75) | VCPPRKDC | |
| SCHEMBL16796140 | 0.82 | VCP (0.59) | VCPRPS6KB1AURKACD38PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | claimed |
| EP-3080101-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | claimed |
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3080101-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | PSMG3, PSMD2, PSME1 | VCP 67/4885RPS6KB1 1162/4885AURKA 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.